Chris Beauchamp, chief market analyst at IG, said: “After the madness of the last three years it looks like Novo’s shares are returning to their longer-term trend – the euphoria that saw the shares reach such dizzying highs has entirely evaporated, but today’s numbers still point to a very healthy business and a long-term opportunity in Wegovy.
Wegovy maker Novo Nordisk boosted by successful weight loss pill launch
